Aigen Investment Management LP Makes New Investment in Haemonetics Co. (NYSE:HAE)

Aigen Investment Management LP acquired a new position in Haemonetics Co. (NYSE:HAE) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,959 shares of the medical instruments supplier’s stock, valued at approximately $479,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Capital Research Global Investors increased its stake in Haemonetics by 2.3% in the 1st quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock worth $569,690,000 after buying an additional 151,183 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Haemonetics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock worth $80,972,000 after purchasing an additional 57,665 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in Haemonetics by 6,573.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock valued at $70,267,000 after purchasing an additional 836,623 shares during the period. Boston Trust Walden Corp lifted its holdings in Haemonetics by 13.8% in the 3rd quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier’s stock worth $65,076,000 after purchasing an additional 98,019 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Haemonetics by 75.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock worth $63,933,000 after purchasing an additional 343,214 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on HAE. Bank of America initiated coverage on shares of Haemonetics in a report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 target price on the stock. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research note on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 13th. CL King initiated coverage on Haemonetics in a research report on Friday, September 13th. They issued a “buy” rating and a $116.00 target price on the stock. Finally, Citigroup cut their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Price Performance

Shares of Haemonetics stock opened at $90.75 on Friday. Haemonetics Co. has a one year low of $70.25 and a one year high of $97.97. The stock has a market cap of $4.56 billion, a price-to-earnings ratio of 38.08, a price-to-earnings-growth ratio of 1.45 and a beta of 0.32. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. The stock has a 50 day moving average price of $76.90 and a 200-day moving average price of $82.71.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The business had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company posted $0.99 earnings per share. Equities analysts expect that Haemonetics Co. will post 4.59 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.